Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Aptinyx Inc (APTX) USD0.01

Sell:$2.63 Buy:$2.64 Change: $0.47 (15.21%)
NASDAQ:0.02%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.63
Buy:$2.64
Change: $0.47 (15.21%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$2.63
Buy:$2.64
Change: $0.47 (15.21%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.

Contact details

Address:
1801 Maple Ave Ste 4300
EVANSTON
60201-3149
United States
Telephone:
+1 (847) 8710377
Website:
https://www.aptinyx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
APTX
ISIN:
US03836N1037
Market cap:
$104.02 million
Shares in issue:
33.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Wilbur Gantz
    Independent Chairman of the Board
  • Norbert Riedel
    President, Chief Executive Officer, Director
  • Ashish Khanna
    Chief Financial Officer, Chief Business Officer
  • Andrew Kidd
    Chief Operating Officer
  • Joseph Moskal
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.